Earnings Summary

Adaptive Biotechnologies Corp’s revenue jumped 12.06% since last year same period to $48.93Mn in the Q2 2023. On a quarterly growth basis, Adaptive Biotechnologies Corp has generated 29.96% jump in its revenue since last 3-months.

Adaptive Biotechnologies Corp’s net profit jumped 8.14% since last year same period to $-47.81Mn in the Q2 2023. On a quarterly growth basis, Adaptive Biotechnologies Corp has generated 22.56% jump in its net profits since last 3-months.

Adaptive Biotechnologies Corp’s net profit margin jumped 18.03% since last year same period to -97.72% in the Q2 2023. On a quarterly growth basis, Adaptive Biotechnologies Corp has generated 40.41% jump in its net profit margins since last 3-months.

Adaptive Biotechnologies Corp’s earning per share (EPS) estimates for the current quarter stand at -0.35 - a 7.89% jump from last quarter’s estimates.

Adaptive Biotechnologies Corp’s earning per share (EPS) estimates for the current year stand at -0.35.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adaptive Biotechnologies Corp’s return on assets (ROA) stands at -0.15.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adaptive Biotechnologies Corp’s return on equity (ROE) stands at -0.42.